Shares of Telix Pharmaceuticals Ltd (TLX.AU) plummeted 8.68% in Wednesday's trading session, following news that the company received a subpoena from the U.S. Securities and Exchange Commission (SEC). The regulatory body is requesting documents and information related to disclosures regarding the development of the company's prostate cancer treatments.

Telix Pharmaceuticals confirmed that it is fully cooperating with the SEC and is in the process of responding to the information request. In a move towards transparency, the company has also decided to notify the Australian Securities and Investments Commission (ASIC) of the SEC's inquiry. This development comes at a crucial time for Telix, as the company recently reported a 63% increase in revenue to $204 million for Q2 2025 and reaffirmed its fiscal year 2025 revenue guidance of $770 million to $800 million.

The sharp stock decline reflects investor concerns about potential regulatory issues and their impact on Telix's prostate cancer pipeline. Analysts at Jefferies have already responded by trimming their price target on Telix Pharmaceuticals to A$34.00 from A$34.50 per share, noting that the regulatory process may take some time to resolve. As the situation unfolds, investors will be closely watching for any updates from the company regarding the SEC inquiry and its potential implications for Telix's business operations and future growth prospects.